U.S. Personal Products Stock News

NYSE:HAE
NYSE:HAEMedical Equipment

Haemonetics (HAE) Is Up 5.3% After FDA Clears NexSys PCS With Persona PLUS Technology

Haemonetics Corporation recently received U.S. Food and Drug Administration 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS technology, supported by a large multicenter trial of over 30,000 plasma donations showing improved average plasma volume per donation while maintaining safety. This next-generation, donor-tailored collection technology could enhance plasma center efficiency and reinforce Haemonetics’ position in high-value plasma collection...
NasdaqCM:PGY
NasdaqCM:PGYSoftware

Is Pagaya (PGY) Turning Short-Term Guidance Volatility Into a Test of Its AI Underwriting Edge?

In recent weeks, Pagaya Technologies reported softer-than-expected first-quarter guidance but reiterated that it is seeing no operational slippage or credit stress, even as broader market volatility weighed on sentiment. Analysts have reaffirmed positive views on the company, arguing that its AI-driven underwriting platform and measured growth outlook remain intact despite short-term market noise. With analysts highlighting management’s reassurance about stable operations, we’ll now...
NYSE:PERF
NYSE:PERFSoftware

Perfect (PERF) Margin Compression Challenges Bullish High‑Growth Narrative After FY 2025 Results

Perfect (PERF) has just wrapped up FY 2025 with Q4 revenue of US$18.1 million and basic EPS of US$0.01, set against trailing twelve month revenue of US$69.2 million and EPS of US$0.05. Over recent quarters the company has seen revenue move from US$15.9 million in Q4 FY 2024 to US$18.1 million in Q4 FY 2025, while quarterly EPS has ranged between about US$0.002 and US$0.025 across FY 2025. This gives investors a clearer view of how growth and profitability are interacting. With a trailing net...
NYSE:JMIA
NYSE:JMIAMultiline Retail

Jumia Technologies (JMIA) Is Down 8.3% After Reporting Narrower 2025 Losses And Higher Sales – Has The Bull Case Changed?

In February 2026, Jumia Technologies AG reported its fourth-quarter and full-year 2025 results, with sales rising to US$61.4 million for the quarter and US$188.93 million for the year, while net losses narrowed to US$10.31 million and US$61.55 million respectively versus the prior year. The company also filed its 2025 Annual Report on Form 20-F with the SEC, offering investors a detailed view of how its pan-African marketplace, logistics network, and payment infrastructure are evolving as it...
NYSE:WBS
NYSE:WBSBanks

A Look At Webster Financial (WBS) Valuation After Recent Share Price Momentum

Webster Financial (WBS) has been drawing fresh attention after recent share price moves, with the stock last closing at $72.42. That brings its reported past 3 months total return to about 21%. See our latest analysis for Webster Financial. The recent 30 day share price return of 13.0% and 90 day share price return of 21.9% sit alongside a 1 year total shareholder return of 34.3%. This points to momentum that has built over a longer horizon rather than just a short term bounce. If Webster...
NYSE:ITGR
NYSE:ITGRMedical Equipment

Integer Holdings (ITGR) One Off US$71.4m Loss Tests Bullish Margin Recovery Narratives

Integer Holdings (ITGR) FY 2025 earnings snapshot Integer Holdings (ITGR) has wrapped up FY 2025 with fourth quarter revenue of $472.1 million and basic EPS of $1.39, rounding out a trailing twelve month EPS of $2.96 on $1.9 billion of revenue and net income of $102.8 million from ongoing operations. The company has seen quarterly revenue range from $437.4 million in Q1 2025 to $476.5 million in Q2 2025. Quarterly EPS moved from a Q1 loss of $0.66 to positive readings of $1.06, $1.13 and...
NYSE:KMI
NYSE:KMIOil and Gas

Kinder Morgan Insider Sale Weighed Against Dividend Growth And Expansion Plans

A senior Kinder Morgan (NYSE:KMI) executive recently sold company shares, drawing investor attention to insider activity. The company announced its ninth consecutive annual dividend increase, extending a long-running pattern of higher payouts. Kinder Morgan highlighted continued investment in large pipeline expansion projects alongside its dividend focus. Kinder Morgan, trading at $32.69, is in the spotlight as investors weigh insider selling against a multiyear record of dividend growth...
NYSE:TRGP
NYSE:TRGPOil and Gas

Targa Resources Expands Permian And Mont Belvieu Capacity For Long Term Growth

Targa Resources (NYSE:TRGP) announced a major build out of natural gas processing plants in the Permian Basin. The company is adding a new large scale NGL fractionator, Train 13, at its Mont Belvieu complex. Targa outlined additional growth projects, including carbon capture initiatives and AI driven technology upgrades across its system. The expansion is described as aimed at meeting rising energy demand tied to data centers and broader market needs. Targa Resources, a large midstream...
NYSE:MAX
NYSE:MAXInteractive Media and Services

MediaAlpha (MAX) Thin 2.3% Net Margin Tests Bullish Profitability Narratives

MediaAlpha FY 2025 Earnings Snapshot MediaAlpha (MAX) has wrapped up FY 2025 with fourth quarter revenue of US$291.2 million and basic EPS of US$0.56, alongside trailing twelve month revenue of about US$1.1 billion and EPS of US$0.46 that sit against earnings growth of 54.1% over the past year. Over the last few quarters, the company has seen revenue range from US$251.6 million to US$306.5 million per quarter. EPS swung from a loss of US$0.33 in Q2 2025 to a profit of US$0.26 in Q3 and...
NasdaqGS:SHC
NasdaqGS:SHCLife Sciences

Sotera Health (SHC) Margin Expansion To 6.7% Tests Premium 60.9x P/E Narrative

Sotera Health (SHC) has put a full year of results on the table, with Q4 FY 2025 revenue of US$303.4 million and basic EPS of US$0.12, rounding out trailing 12 month revenue of about US$1.2 billion and EPS of US$0.27 that follows earnings growth of 75.8% over the past year. Over recent quarters the company has seen revenue move from US$254.5 million in Q1 FY 2025 to US$311.3 million in Q3 and US$303.4 million in Q4. Quarterly basic EPS has ranged from a loss of US$0.05 in Q1 to US$0.17 in Q3...
NYSE:EXPD
NYSE:EXPDLogistics

Expeditors International Of Washington (EXPD) Flat TTM Earnings Challenge Bullish Quality Narrative

Expeditors International of Washington (EXPD) just wrapped up FY 2025 with fourth quarter revenue of US$2.9 billion and basic EPS of US$1.50, alongside net income of US$200.7 million. Together, these results set the tone for how the full year will be judged. Over recent quarters, the company has seen revenue range from US$2.7 billion to US$3.0 billion, while quarterly EPS moved between roughly US$1.35 and US$1.69. This gives investors a clearer view of how the top and bottom lines have...
NasdaqGS:ARM
NasdaqGS:ARMSemiconductor

Arm’s AI Royalties Surge and Nvidia Exit Might Change The Case For Investing In ARM (ARM)

Arm Holdings recently reported record fiscal Q3 revenue growth driven by higher royalty and licensing demand tied to AI-focused chip designs, while Nvidia completed the sale of its roughly US$140 million minority stake, ending its equity ownership but keeping their technology relationship intact. At the same time, Malaysia is pushing an agreement to use Arm’s intellectual property to build a local chip-design ecosystem, underlining Arm’s growing global importance in AI and semiconductor...
NasdaqCM:ESTA
NasdaqCM:ESTAMedical Equipment

Establishment Labs Holdings (ESTA) Q4 Loss NARROWS Sharply Reinforcing Bullish Profitability Narrative

Establishment Labs Holdings (NasdaqCM:ESTA) just wrapped FY 2025 with Q4 revenue of US$64.6 million and a basic EPS loss of US$0.09, alongside trailing twelve month revenue of US$211.1 million and a TTM basic EPS loss of US$1.72. The company has seen quarterly revenue move from US$40.2 million in Q3 2024 to US$64.6 million in Q4 2025, while quarterly basic EPS losses shifted from US$1.19 in Q4 2024 to US$0.09 in Q4 2025, setting up an earnings story where stronger top line figures are still...
NasdaqGS:COGT
NasdaqGS:COGTBiotechs

Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk

Cogent Biosciences (NasdaqGS:COGT) has advanced its lead therapy bezuclastinib into a Phase 3 trial for systemic mastocytosis. The company has also filed a significant shelf registration that could be used to raise capital in the future. These updates highlight progress in Cogent Biosciences' clinical pipeline alongside preparations for potential funding needs. Cogent Biosciences enters this news cycle with its shares at $39.18 and very large 1 year returns, reflecting strong recent...
NasdaqGS:UPBD
NasdaqGS:UPBDSpecialty Retail

Upbound Group (UPBD) Margin Hit And One Off Loss Challenge Bullish Growth Narrative

Upbound Group (UPBD) has wrapped up FY 2025 with Q4 revenue of US$1.2 billion and basic EPS of US$0.35, while trailing twelve month figures show revenue of US$4.7 billion and EPS of US$1.30 against a current share price around US$21.62. Over the past six quarters, the company has seen revenue move from US$1.08 billion in Q4 2024 to US$1.20 billion in Q4 2025, with quarterly EPS ranging between US$0.23 and US$0.57 along the way. This gives investors a clear view of how the top line and per...
NasdaqGS:ASML
NasdaqGS:ASMLSemiconductor

Assessing ASML Holding (NasdaqGS:ASML) Valuation After A Strong Year Of Shareholder Returns

ASML Holding stock performance and business snapshot ASML Holding (NasdaqGS:ASML) has drawn investor attention recently, with the share price at $1,497.80 and total returns over the past year, 3 years, and 5 years all in positive territory. The company reports annual revenue of €32.67b and net income of €9.61b, with both revenue and earnings showing positive annual growth. ASML focuses on lithography, metrology, and inspection systems used in advanced semiconductor manufacturing. Its...
NasdaqGS:TARS
NasdaqGS:TARSPharmaceuticals

Tarsus Pharmaceuticals (TARS) Narrowing EPS Loss Backs Bullish Earnings Turnaround Narrative

Tarsus Pharmaceuticals (TARS) closed FY 2025 with fourth quarter revenue of US$151.7 million and a basic EPS loss of US$0.20, while net income excluding extra items came in at a loss of US$8.4 million. The company has seen quarterly revenue move from US$48.1 million and a basic EPS loss of US$0.61 in Q3 2024 to US$151.7 million and a loss of US$0.20 per share in Q4 2025. Trailing twelve month EPS stands at a loss of US$1.59 on revenue of US$451.4 million, outlining a picture where higher...
NasdaqGS:GLDD
NasdaqGS:GLDDConstruction

Great Lakes Dredge & Dock (GLDD) Net Margin Beats Narratives Of Future Compression

Great Lakes Dredge & Dock (GLDD) capped FY 2025 with Q4 revenue of US$256.5 million and basic EPS of US$0.19, rounding out a trailing twelve month picture that includes total revenue of US$888.3 million and EPS of US$1.10. Over the past few quarters, the company has seen revenue move from US$191.2 million in Q3 2024 to US$202.8 million in Q4 2024, then to US$242.9 million in Q1 2025 and US$195.2 million in Q3 2025, with quarterly EPS ranging from US$0.13 to US$0.50 over the same stretch. This...
NasdaqGS:PTLO
NasdaqGS:PTLOHospitality

Portillo’s (PTLO) Margin Compression To 2.6% Tests Bullish Profit Growth Narrative

Portillo's (PTLO) has wrapped up FY 2025 with fourth quarter revenue of US$185.7 million and basic EPS of US$0.08, alongside net income of US$6.1 million. This update gives investors an opportunity to reassess how the full year stacks up against its recent history. The company has seen quarterly revenue move from US$176.4 million in Q1 2025 to a range between US$181.4 million and US$188.5 million through the year, while EPS shifted between US$0.02 and US$0.13, giving a mixed read on profit...
NYSE:CYD
NYSE:CYDMachinery

China Yuchai International Earnings Growth Tests Bearish Narratives On Long Term Profitability

China Yuchai International (NYSE:CYD) has just posted its FY 2025 first half numbers, with revenue of C¥13.8b and basic EPS of C¥9.75, setting the tone for a year in which investors are closely tracking how earnings and sales are holding up. The company has seen revenue move from C¥10.3b in the first half of 2024 to C¥13.8b in the first half of 2025, while basic EPS went from C¥5.88 to C¥9.75 over the same period. With trailing 12 month EPS at C¥14.32 on revenue of C¥24.7b, the results put...
NYSE:EFX
NYSE:EFXProfessional Services

AI Credit Planner Launch Amid Rising Borrower Stress Could Be A Game Changer For Equifax (EFX)

In February 2026, Equifax launched Optimal Path, an AI-powered, interactive credit score planner that provides U.S. consumers with personalized, evolving 30-day action plans via the free myEquifax mobile app, integrating directly with their Equifax credit profiles. Alongside this product rollout, fresh Equifax credit data underscored widening financial stress for younger and highly leveraged borrowers, reinforcing the importance of real-time, personalized credit tools and positioning...
NYSE:OSG
NYSE:OSGInsurance

Octave Specialty Group NYSE OSG Combined Ratios Above 100% Reinforce Bearish Underwriting Narratives

Octave Specialty Group (OSG) just posted its FY 2025 numbers with Q4 total revenue of US$66.9 million and a basic EPS loss of US$0.66, while on a trailing twelve month basis revenue came in at US$251.2 million and EPS at a loss of US$2.09. The company has seen quarterly revenue move from US$65.2 million in Q4 FY 2024 to US$66.9 million in Q4 FY 2025, with basic EPS shifting from a loss of US$0.46 to a loss of US$0.66 over the same period. This sets the stage for investors to focus squarely on...
NasdaqGS:VNET
NasdaqGS:VNETIT

Does VNET Group’s (VNET) Finance Shake-Up Clarify Its Complex Capital Structure Or Deepen Uncertainty?

VNET Group, Inc. recently appointed Peter Zhihua Zhang as Senior Vice President of Operational Finance and principal accounting officer, giving him authority over financial operations and key SEC and Nasdaq filings while the company amended its US$250 million 2% convertible senior notes due 2027 with Blackstone-managed vehicles. The combination of a strengthened internal finance leadership role and changes to the convertible note terms has refocused attention on VNET’s governance, capital...
NYSE:JLL
NYSE:JLLReal Estate

Is It Time To Reassess JLL (JLL) After Recent Share Price Swings?

If you are wondering whether Jones Lang LaSalle is priced attractively today, a good starting point is understanding what the recent share moves are really telling you about value and risk. The stock last closed at US$310.97, after a 7 day return of 8.4%, a 30 day return showing a 12.2% decline, and returns of a 7.4% decline year to date and 17.1% over the past year, with longer term returns of 78.2% over 3 years and 74.5% over 5 years. Recent news around Jones Lang LaSalle has focused on...